Mentor, mother, activist, advocate, sister, survivor, researcher and Fred Hutch friend, Bridgette Hempstead died last month ...

Referring to cancer as a “battle” minimizes the many real issues faced by cancer patients who must live with nausea, pain, ...

In addition to using gemcitabine and the natural killer cells that are TGF-β imprinted, we also are combining an anti-GD2 antibody called naxitamab that's provided by Y-mAbs. Naxitamab, as I said, is ...

New study successfully made CTC-derived organoids from breast cancer patients' blood samples to investigate cell survival and ...

Mersana shares Phase 1 data on Emi-Le for TNBC and details FDA's Fast Track status for XMT-1660 in advanced HER2-low breast ...

Mersana Therapeutics (MRSN) stock hits a 52-week low in reaction to early clinical results for its cancer drug Emi-Le in ...

For female patients aged at least 66 years, odds of prevalent CVD up with locally advanced and metastatic disease.

Another new year, another half-billion-biobuck transaction between Insilico Medicine and the Italian drugmaker Menarini Group ...

TrialTranslator uses machine learning to assess cancer RCT generalizability, revealing survival gaps for high-risk patients ...

Arvinas (ARVN) announced updated guidance for the planned first- and second-line combination clinical trials for vepdegestrant in patients with ...

Patients with HR+/HER2− metastatic breast cancer without previous systemic therapy were randomly assigned to receive either ...

Mersana on Friday said the new designation covers the drug, XMT-1660, for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or ...